Sign or Symptom – Page 3

Vertex’s Non-Opioid Pain Drug, Suzetrigine (VX-548), Shows Promising Results in Phase III Trials, Aiming for FDA Approval

6 months ago talkbio0Tagged Acute onset pain, Approved, non-opioid pain drug, Opioids, Phase 3 Clinical Trials, Suzetrigine, United States Food and Drug Administration, VX-548

Non-opioid pain drug, Suzetrigine (VX-548), Vertex Pharmaceuticals, Phase III trials, acute pain, FDA approval, opioid alternative

FDA Approves Avadel’s Lumryz for Pediatric Narcolepsy Patients

6 months ago talkbio0Tagged Approved, Avadel, Cataplexy, Daytime Somnolence, Excessive (qualifier value), Excessive Daytime Sleepiness, LUMRYZ, Narcolepsy, Pediatric brand name, sodium oxybate, United States Food and Drug Administration

Avadel Pharmaceuticals, Lumryz, narcolepsy, pediatric patients, FDA approval, sodium oxybate, cataplexy, excessive daytime sleepiness (EDS)

Enanta Pharmaceuticals Achieves Breakthrough in RSV Treatment with EDP-323, Demonstrating Significant Reductions in Viral Load and Symptoms

7 months ago talkbio0Tagged Alleviation, antiviral treatment, EDP-323, Enanta, Human Challenge Study, phase 2a, Respiratory syncytial virus, Symptoms, Viral Load result

Enanta Pharmaceuticals, EDP-323, Respiratory Syncytial Virus (RSV), Antiviral Treatment, Phase 2a Human Challenge Study, Viral Load Reduction, Symptom Alleviation

Roche’s Obesity Pill Candidate Faces Safety Concerns Amid Promising Efficacy Results

7 months ago talkbio0Tagged aspects of adverse effects, concerns, Contraceptives, Oral, CT-996, Effectiveness, Gastrointestinal Issues, Nausea, Obesity, Roche (company), Safety, Vomiting

Roche, Obesity Pill, Safety Concerns, Efficacy Data, CT-996, Side Effects, Nausea, Vomiting, Gastrointestinal Issues

Enhancing Flu Vaccine Uptake in the Post-Pandemic Era: Strategies and Insights

8 months ago talkbio0Tagged Health Personnel, historical period, Post-Pandemic, public health strategies, Uptake, Urinary hesitation, Vaccination, Vaccines

flu vaccine uptake, post-pandemic era, vaccine hesitancy, public health strategies, healthcare providers, influenza vaccination

Galderma’s Nemluvio Receives FDA Approval for Prurigo Nodularis Treatment

8 months ago talkbio0Tagged Approved, chronic skin condition, Galderma, IL31 gene, Inhibitor, Nemluvio, Prurigo nodularis, Pruritus, United States Food and Drug Administration

Nemluvio, Galderma, FDA Approval, Prurigo Nodularis, IL-31 Inhibitor, Chronic Skin Condition, Itch Treatment

Aldeyra’s Reproxalap Demonstrates Efficacy in Reducing Eye Discomfort in New Phase 3 Study

8 months ago talkbio0Tagged Discomfort, Dry Eye Syndromes, Eye, Phase 3 Clinical Trials, Rejection (Psychology), reproxalap, United States Food and Drug Administration

Aldeyra Therapeutics, Reproxalap, Phase 3 Study, Eye Discomfort, Dry Eye Disease, FDA Rejection

FDA Decision on Vertex’s Non-Opioid Analgesic Suzetrigine Due Early Next Year

9 months ago talkbio0Tagged Acute onset pain, Analgesics, Non-Opioid, PDUFA, Priority Review, Suzetrigine, United States Food and Drug Administration, Vertex

FDA, Vertex, Suzetrigine, Non-Opioid Analgesic, Acute Pain, PDUFA, Priority Review

MEI Pharma’s Leadership Shakeup: CEO and Medical Head Step Down Amidst Wind-Down Considerations

9 months ago talkbio0Tagged CEO, Flatulence, MEI, Pharma, strategic alternatives

MEI Pharma, wind down, CEO, medical head, strategic alternatives

Lexeo Therapeutics Reports Promising Early Data for Gene Therapy LX2006 in Friedreich Ataxia Cardiomyopathy

9 months ago talkbio0Tagged Ataxia, Cardiomyopathies, Clinical Trials, gene therapy, Hereditary Diseases, Infrequent, Lexeo, LX2006

Lexeo Therapeutics, LX2006, Gene Therapy, Friedreich Ataxia, Cardiomyopathy, Clinical Trials, Rare Genetic Disorders